Garlan Adams joins Crinetics Pharmaceuticals as first General Counsel
Crinetics Pharmaceuticals, a clinical stage pharmaceutical announced the appointment of Garlan Adams (pictured) to the newly created role of general counsel. Adams brings to Crinetics more than two decades of experience managing legal and compliance matters associated with the development and commercialization of pharmaceutical and biotechnology products.
Prior to joining Crinetics pharma, Garlan Adams was an independent consultant and business advisor. For a period of around 4 years, she was general counsel at Avanir Pharmaceuticals. Earlier in her career, Adams held positions of increasing responsibility at Eli Lilly & Company, Amylin Pharmaceuticals, Amgen and Onyx Pharmaceuticals, where she provided counsel on product labeling, launch readiness and on matters related to medical affairs, manufacturing, sales, marketing, pricing and compliance.
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.